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Objectives: This study evaluated the Xpert HPV Assay in women attending screening in general practice
by comparing Xpert with two established HPV tests, cytology and histology.
Methods: A prospective study in women aged 20–60 years attending screening in Bristol, Edinburgh and
London using residual Preservcyt cytology samples. Sample order was randomised between Roche
cobas4800 and Cepheid Xpert assays with Qiagen hc2 third.
Results: 3408 cases were included in the primary analysis. Positivity for Xpert was 19.6%, cobas 19.2% and
hc2 19.9% with high concordance (kappa¼86.8% vs cobas, 81.55 vs hc2). Xpert, cobas and hc2 showed
similar sensitivity (98.7%, 97.5%, 98.7%) for CIN2þ . All pairwise comparisons had high concordance
(Kappa Z0.78 with any abnormal cytology. Xpert and hc2 were positive for all cases of Zmoderate
dyskaryosis (N¼63)), cobas was negative in two. Histology was available for 172 participants. 79 reported
CIN2þ , 47 CIN3þ . All CIN3þ was positive on Xpert and hc2 and one case negative for cobas. One case of
CIN2 was negative for all assays.
Conclusions: The performance of Xpert HPV Assay in a general screening population is comparable to
established HPV tests. It offers simplicity of testing, ﬂexibility with non-batching of individual samples
and rapid turnaround time.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Human Papillomavirus (HPV) testing is increasingly being
recognised as the best method for primary cervical screening
because of its very high sensitivity [1–3]. There are a number of
HPV tests currently available, but they all require a high degree of
laboratory expertise and sophisticated platforms which are gen-
erally more efﬁcient when samples are run as full batches. The
Xpert HPV Assay (Cepheid, Inc, Sunnyvale, CA) is a real-time
Polymerase Chain Reaction (PCR) assay, using disposable car-
tridges, for the detection of 14 types of high-risk HPV DNA (types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) from a liquid
cytology sample. The assay is run on the Cepheid GeneXpert
System which is a scalable, random access instrument platform.
Its capacity ranges from one to 80 tests in simultaneous, but
asynchronous assays which can be run for the same or different
assays according to the cartridge used. Results are typically
available in 60–90 min depending on the assay. An early and
now widespread use of the platform was to diagnose tuberculosis
and distinguish drug resistant strains in low and intermediate
income countries [4]. Other uses include testing for a range of
infectious agents. There are now over 8500 platforms in use
throughout the world.
To date, performance of the Xpert HPV Assay using samples
derived from referral populations have been comparable to those
of currently available clinically validated tests [5,6]. The objective
of this study was an evaluation of the Xpert HPV Assay in a
screening population using residual cervical cytology PreservCyt
specimens originally obtained from women aged 20–60 years.
Performance of the Xpert HPV Assay was compared to two
established HPV DNA tests and with cytology and histopathology.
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2. Methods
There were four sites in this study: 3 clinical and also
1 reference. The external reference site gave blind testing and
standardised conditions for the primary comparator – cobas 4800.
The three clinical sites were Bristol, Edinburgh and London.
Samples were originally collected from women attending for
routine cervical screening as part of the UK NHSCSP in PreservCyt
liquid cytology using a Cervex brush (Rovers Medical Devices B.V.,
Oss, Netherlands) or similar. A residual specimen was the remain-
ing PreservCyt sample, kept at room temperature, after the
completion of routine clinical testing (cytology evaluation and,
where applicable, high-risk HPV triage). A satisfactory cytology
result (with or without HPV triage) and sufﬁcient remaining
sample volume to carry out at least two HPV tests (minimum
8 ml PreservCyt) was required. Sample size calculations were done
separately for women aged 20–29 years and aged 30–60. An HPV
prevalence of 25% in the younger women and 8.7% in the older age
group resulted in minimal sample sizes of 900 and 2600 respec-
tively to be able to have 95% power to ensure that the lower 2-
sided 95% CI for kappa would be above 0.75 when the true value
was 0.82 for cobas and above 0.65 when the true value was 0.75
for hc2 for each age group. Assumed true kappa values were based
on previous studies [7,8].
The samples were collected from women who had originally
attended screening between July 2013 and January 2014. Popula-
tions were somewhat different as the screening algorithms were
different in the 3 centres leading to different positivity rates. In
order to obtain 900 women in the 20–29 age group, this was
oversampled in Edinburgh, as screening begins at age 20 years in
Scotland and 25 years in England. Also in Scotland women who
had borderline or mildly dyskaryotic smears were followed by
repeat short term cytology and not triaged with HPV to determine
if they should be referred immediately, so that these women were
also included in the sample from Edinburgh. However within each
centre samples were collected at random from each age stratum.
The primary comparison was between the Xpert HPV Assay and
the Roche cobas 4800 HPV test (Roche Diagnostics, Basel, Switzer-
land) with a secondary comparison between Xpert HPV Assay and
the hc2 test (QIAGEN, Gaithersberg, MD). Aliquot order was either
by method 1, where odd numbered specimens had an aliquot for
cobas detection taken ﬁrst and Xpert second and vice versa for
even numbers or method 2 where batches of 100 specimens were
divided into 2 halves with the ﬁrst 50 having an aliquot for cobas
detection taken ﬁrst and Xpert second and the next 50 having the
Xpert ﬁrst and cobas second. The aliquot for hc2 was always taken
third. The original specimen in the ThinPrep pot was mixed either
by inverting 8–10 times or brieﬂy vortexing for 5–10 s prior to the
removal of each aliquot. The cobas aliquot (volume 2 ml) was
stored at room temperature (15–25 1C) and dispatched to the
reference laboratory in Liverpool where testing was conducted in
accordance with the manufacturer's instructions. The Xpert HPV
Assay was conducted onsite in laboratories in Bristol, Edinburgh
and London. The aliquot (volume 1.2 ml) was stored at room
temperature (15–25 1C) prior to testing. Testing was carried out
within six weeks of sample collection in accordance with manu-
facturer's instructions. The aliquot for hc2 testing (volume 4 ml or
2 ml depending upon whether a manual or Rapid Capture System
processing method was used) was stored at room temperature or
refrigerated (2–30 1C) and tested onsite within six weeks, as per
manufacturer's instructions.
Detailed technical descriptions of the Xpert HPV Assay have
been reported elsewhere [5]. Brieﬂy, the E6 and E7 genes of the 14
targeted HR HPV types are ampliﬁed simultaneously in ﬁve
ﬂuorescent channels: HPV16; HPV18/45; HPV31/33/35/52/58;
HPV51/59; and HPV39/56/66/68. A specimen adequacy control,
HMBS, is detected in a sixth channel. Assay results were reported
as an overall “positive” if any of these types were detected, with
HPV16 and HPV 18/45 reported separately.
The cut-off for positivity with the Xpert HPV Assay waso40Ct
for HPV 16 and HPV 18/45, and o38 Ct for HPV 31/35/33/52/58,
HPV 51/59, and HPV 39/68/56/66. Positivity for Cobas was o40Ct
for HPV 31/33/35/39/45/51/52/56/58/59/66/68 and HPV16 and
o40.5 Ct for HPV 18 and41 RLU for hc2.
Positivity rates and agreement of the Xpert Assay with the Cobas
(primary comparator) and high-risk hc2 (secondary comparator) were
evaluated. Referral to colposcopy was only based on the cytology
result, with or without HPV triage according to local protocols. The
triage tests used were Abbott RealTime in London and hc2 and Aptima
in Bristol. Scotland, at the time of the study, started routine cervical
screening at age 20 years whereas in England it was age 25 years. The
Edinburgh centre therefore had a younger age distribution. Scotland is
due to change to 25 years in 2016. Triage also differed between the
two countries. In England, but not Scotland, borderline squamous or
mildly dyskaryotic cytology is followed by HPV triage testing. Those
women testing negative are followed up with repeat cytology whereas
those testing positive are referred for colposcopic examination, where
histopathology samples may be taken for further assessment. In
Scotland there is currently no HPV triage and women are referred
for colposcopy only after more than one consecutive low grade
cytology result. Women with higher grade cytology results were
referred for colposcopic assessment in all centres [9,10]. Histology
results for the English sites were collected up to 12 months after
cytology but this was extended to 18 months for Edinburgh in view of
the different referral guidelines. The HPV results from this study were
not used for patient management, so that lesions in women with
negative cytology could not be identiﬁed.
Ethics approval was received from National Research Ethics
Service Committee East Midlands – Leicester (reference: 13/EM/
0244) on 10th June 2013. Individual informed consent was not
required as the study was non-invasive and the samples would
otherwise have been discarded. In addition the residual samples
were pseudo-anonymised and only identiﬁable to the research
team by subject number. Cytology data and histopathology data
were linked to the HPV result by the centre and then all data were
pseudo-anonymised before release to the statistical centre and
were only identiﬁable by subject number.
3. Results
A total of 3529 samples were collected. Of these 15 women were
found to be ineligible and another 106 samples did not produce a valid
result for both Xpert and cobas leaving 3408 women in the primary
analyses (Fig. A1) with all three tests valid, no hc2 tests were invalid.
Their demographic and cytology details are shown in Table B1. The
median age was 38 years and 76% were aged 30 years or older, but the
Edinburgh cohort was younger due a policy of screening from age 20
years. The negative cytology rate of 87% overall ranged from 98% in
Bristol to 80% in Edinburgh and 84% in London. 63 (2%) women had
moderate or severe dyskaryosis on cytology with Edinburgh account-
ing for 48 of these. A further 370 (11%) women overall had borderline
or mild dyskaryosis. Bristol had a very low rate of low grade
abnormality (2% compared to 15% in Edinburgh and 16% in London).
Positivity by test, age group, and cytology and histology outcome is
shown in Table C1. 19.6% of all women were positive by Xpert HPV
Assay compared with 19.2% with cobas and 19.9% with hc2.
Supplementary Table 1 shows that there was variation of positivity
rates by centre reﬂecting the differences above in positivity in cytology,
with Bristol reporting 12% positive with Xpert, 12% with Cobas and
12% with hc2 compared to Edinburgh 25%, 25% and 26% respectively
and London 21%, 21% and 22% respectively.
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Table C1 also shows that Xpert and hc2 were positive for all cases
of high grade cytology whereas cobas was negative for 2 cases, in
women aged 29 years. Xpert and hc2 were also positive for all cases of
CIN3þ , whereas cobas was negative for one women aged 29 (who
was one of the women with abnormal cytology). In addition a 31 year
old woman with CIN2 on excisional biopsy was negative for each HPV
test. Her original cytology result was reported as low grade but she
had a subsequent moderate result and her excision histology result
was 11 months after her sample for HPV testing was taken.
Concordant and discordant outcomes between Xpert and the
other two tests are shown in Table D1. High levels of agreement in
HPV positivity were seen between Xpert and the other two tests
(95.8% for cobas and 94.1% for hc2). Discordant pairs were of
similar number in each direction reﬂecting similar overall positiv-
ity rates. All tests were positive for all high grade cytology and
almost all CIN2þ . Cobas was negative for two cases of high grade
cytology. One subsequently had CIN3 on excision biopsy whereas
the other had no CIN on histology. All three tests showed similar
speciﬁcity for CIN2þ (82–83%) and CIN3þ (81–82%) and also
similar positivity predictive values. However both of these were
age dependent with speciﬁcity being substantially higher in
women aged 30–60, but PPV higher in women aged 20–29 years
than for women aged 30–60 years. Negative predictive values
were all above 99.8% (data not shown). Supplementary Table 2
breaks these numbers down by site.
HPV 16 was reported separately for the Xpert and cobas assays.
For Xpert positivity rates for HPV16 were 5% overall and 14% for
women aged 21–29 and 2% for ages 30–60. For cobas the
corresponding rates were the same 5%, 14% and 2%. Table D1
shows the concordance rate was very high being 99.0% with a
kappa value of 90.1% and similar numbers of discordants in each
direction.
4. Discussion
This is the ﬁrst study to assess the performance of the Xpert
HPV Assay in a screening population. The data suggest that the
performance of Xpert is highly comparable to two clinically
validated tests (cobas 4800 and hc2). Xpert HPV Assay offers more
extensive partial typing than cobas which reports HPV 16 and HPV
18 and a consensus positivity for 12 other high risk HPV types. Hc2
does not offer individual typing but a consensus result for 13 high
risk types. The Xpert HPV Assay also has the advantage that results
are available within a short timeframe (the assay run time is under
1 h) with the ﬂexibility to run a single or multiple cartridges. The
system is very accessible operationally, requiring simple vortexing
of the ThinPrep pot and pipetting into the single cell cartridge
which is then slotted into the GeneXpert machine. This ﬂexibility
with non-batching and rapid turnaround time of individual
samples could prove particularly useful in laboratory and clinical
settings where workload is variable.
The sensitivity and speciﬁcity results in this study were similar
across centres, despite their different disease rates. However these
are relative measures since colposcopy referral was based only on
routine procedures and so some disease in cytology negative
women may have been missed.
There were differences between centres in the proportion of
abnormal histology and cytology and HPV prevalence. There are a
number of possible explanations for this. Women under 25 years
were targeted in Edinburgh whereas there were very few in
London and Bristol where screening commences at 25 years,
although invitations can be sent six months earlier. Subsequently
there were differences between centres in the age distribution. In
addition there were different referral policies between England
and Scotland. For example Bristol has incorporated HPV triage as
part of screening for substantially longer than London, and this
was not used at all in Edinburgh at the time of this study so that
those from Edinburgh with up to two low risk cytology results
were kept within the ‘screening’ population. The higher HPV and
disease rate in Edinburgh had the advantage or providing more
CIN2þ cases overall which increased the accuracy of the sensitiv-
ity estimates. However, no differences between the performance
of the three HPV tests was seen across the different centres.
Overall the HPV prevalence was only slightly higher here than
that previously recorded in a similar English population as part of
the ARTISTIC Study (19.9% versus 16.1% using hc2), but ARTISTIC
used a 2RLU cut-off for hc2. Cytology results were also virtually
identical with 10.9% low grade and 1.9% high grade abnormalities
for both studies [11]. Lastly histology was assessed locally without
central review, so there could be local differences in interpretation
across centres.
In conclusion, this study shows that the Xpert HPV Assay is a
useful additional to the HPV testing market and compares well in
terms of performance with other more established HPV testing
systems. A study in which the HPV result is used for clinical
management is needed to demonstrate the added sensitivity of
this test in cytology negative women and directly compare its
performance to cytology.
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See Fig. A1.
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Fig. A1. Flowchart of women in this screening study.
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Appendix B
See Table B1.
Appendix C
See Table C1.
Appendix D
See Table D1.
Appendix E
See Table E1.
Table C1
HPV positivity by test, age group, cytology and histology result.
Age (y) Cytology Histology
N (% of all with same cytology and age) N (% of all with same histology and age)
Total Normal Low grade High grade All CIN2þ CIN3þ
20–29 604 180 43 827 52 33
30–60 2371 190 20 2581 27 14
All 2975 370 63 3408 79 47
Xpert þve
20–29 160 (26.5) 133 (73.9) 43 (100) 336 (40.6) 52 (100) 33 (100)
30–60 214 (9.0) 98 (51.6) 20 (100) 332 (12.9) 26 (96.3) 14 (100)
All 374 (12.6) 231 (62.4) 63 (100) 668 (19.6) 78 (98.7) 47 (100)
Cobas þve
20–29 163 (27.0) 132 (73.3) 41 (95.3) 336 (40.6) 51 (98.1) 32 (97.0)
30–60 199 (8.4) 98 (51.6) 20 (100) 317 (12.3) 26 (96.3) 14 (100)
All 362 (12.2) 230 (62.2) 61 (96.8) 653 (19.2) 77 (97.5) 46 (97.9)
hc2 þve
20–29 143 (23.7) 135 (75.0) 43 (100) 321 (38.8) 52 (100) 33 (100)
30–60 224 (9.4) 113 (59.5) 20 (100) 357 (13.8) 26 (96.3) 14 (100)
All 367 (12.3) 248 (67.0) 63 (100) 678 (19.9) 78 (98.7) 47 (100)
Table B1
Demographics and cytology results.
Bristol Edinburgh London All
N (% site total) N (% site total) N (% site total)
Number included 1147 1132 1129 3408
Age
Median (IQR) 41 (32–49) 38 (29–48) 35 (28–44) 38 (30–47)
Z30y 953 (83.1) 844 (74.6) 784 (69.4) 2581 (75.7)
Cytology
Negative 1120 (97.6) 911 (80.5) 944 (83.6) 2975 (87.3)
Borderline or mild 18 (1.6) 173 (15.3) 179 (15.8) 370 (10.9)
High grade or glandular 9 (0.8) 48 (4.2) 6 (0.5) 63 (1.8)
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Appendix F. Supplementary Information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.pvr.2015.05.002.
References
[1] J. Cuzick, L. Cadman, D. Mesher, et al., Comparing the performance of six
human papillomavirus tests in a screening population, Br. J. Cancer 108 (4)
(2013) 908–913.
[2] D.C. Rijkaart, J. Berkhof, F.J. van Kemenade, et al., Evaluation of 14 triage
strategies for HPV DNA-positive women in population-based cervical screen-
ing, Int. J. Cancer 130 (3) (2012) 602–610.
[3] A. Szarewski, D. Mesher, L. Cadman, et al., Comparison of seven tests for high-
grade cervical intraepithelial neoplasia in women with abnormal smears: the
Predictors 2 study, J. Clin. Microbiol. 50 (6) (2012) 1867–1873.
[4] G. Meyer-Rath, K. Schnippel, L. Long, et al., The impact and cost of scaling up
GeneXpert MTB/RIF in South Africa, PloS One 7 (5) (2012) e36966.
[5] P.E. Castle, K.M. Smith, T.E. Davis, et al., Reliability of the Xpert HPV assay to
detect high-risk human Papillomavirus DNA in a colposcopy referral popula-
tion, Am. J. Clin. Pathol. 143 (1) (2015) 126–133.
[6] M.H. Einstein, K.M. Smith, T.E. Davis, et al., Clinical evaluation of the cartridge-
based GeneXpert Human Papillomavirus assay in women referred for colpo-
scopy, J. Clin. Microbiol. 52 (6) (2014) 2089–2095.
[7] M.H. Stoler, T.C. Wright Jr., A. Sharma, R. Apple, K. Gutekunst, T.L. Wright,
High-risk human papillomavirus testing in women with ASC-US cytology:
results from the ATHENA HPV study, Am. J. Clin. Pathol. 135 (3) (2011)
468–475.
[8] T.C. Wright Jr., M.H. Stoler, C.M. Behrens, R. Apple, T. Derion, T.L. Wright, The
ATHENA human papillomavirus study: design, methods, and baseline results,
Am. J. Obstet. Gynecol. 206 (1) (2012) 46.e1–46.e11.
[9] Programme NCS. Colposcopy and Programme Management. Guidelines for th
NHS Cervical Screening Programme – Publication 20. In: D L, S L, editors. 2 ed:
NHS Cancer Screening Programme; 2010.
[10] Scotland N. Colposcopy and Programme Management. Addendum to NHSCSP
Publication No 20 s Edition – Exceptions Applicable in NHS Scotland. In:
Programme SCS, editor.; 2013.
[11] H.C. Kitchener, M. Almonte, P. Wheeler, et al., HPV testing in routine cervical
screening: cross sectional data from the ARTISTIC trial, Br. J. Cancer 95 (1)
(2006) 56–61.
Table D1
Discordant results according to test – overall and according to cytology and histology categories. Differences for HPV16 between Xpert and cobas shown as ﬁnal column.
Population/Concordance Xpert vs Cobas Xpert vs hc2 Cobas vs hc2 Xpert vs Cobas HPV 16
All – N¼3408
Agreement (%) 95.8 94.1 93.7 99.0
Kappa (95%CI) 86.6 (84.4–88.7) 81.5 (79.0–84.0) 79.9 (77.4–82.5) 90.1 (86.7–93.4)
Discordanta 79 vs 64 95 vs 105 95 vs 105 19 vs 14
OR (95% CI) 1.23 (0.9–1.7) 0.90 (0.7–1.2) 0.79 (0.6–1.0) 1.4 (0.6–2.9)
Normal Cytology – N¼2975
Agreement (%) 96.0 94.3 94.1 99.2
Kappa (95%CI) 81.4 (78.2–84.6) 73.9 (70.2–77.7) 72.6 (68.8–76.5) 83.6 (77.1–90.0)
Discordanta 66 vs 54 88 vs 81 85 vs 90 16 vs 8
OR (95% CI) 1.22 (0.8–1.8) 1.09 (0.8–1.5) 0.94 (0.7–1.3) 2.0 (0.8–5.4)
All abnormal cytology – N¼433
Agreement (%) 94.7 92.8 90.8 97.92
Kappa (95%CI) 87.9 (83.1–92.7) 83.0 (77.3–88.8) 78.3 (71.9–84.6) 94.2 (0.9–1.0)
Discordanta 13 vs 10 7 vs 24 10 vs 30 3 vs 6
OR (95% CI) 1.30 (0.5–3.3) 0.292 (0.1–0.7) 0.33 (1.5–0.7) 0.5 (0.1–2.3)
Low grade cytology (borderline and mild) – N¼370
Agreement (%) 94.3 92.8 89.7 98.1
Kappa (95%CI) 87.9 (83.9–92.9) 83.0 (77.3–88.8) 77.6 (70.9–84.3) 93.7 (89.1–98.3)
Discordanta 11 vs 10 7 vs 24 10 vs 28 1 vs 6
OR (95% CI) 1.1 (0.4–2.9) 0.29 (0.1–0.7) 0.36 (0.2–0.8) 0.2 (0–1.4)
High grade cytology (CIN2þ) – N¼63
Agreement (%) 96.8 100 96.8 96.8
Discordanta 2 vs 0 0 vs 0 0 vs 2 2 vs 0
Histology (CIN2þ) – N¼79
Agreement (%) 98.7 100 100 96.2
Discordanta 1 vs 0 0 vs 0 0 vs 1 2 vs 1
Histology (CIN3þ) – N¼47
Agreement (%) 97.9 – 97.9 95.7
Discordanta 1 vs 0 0 vs 0 0 vs 1 2 vs 0
a Xpert positive/cobas negative vs Xpert negative/cobas positive.
Table E1
Sensitivity, positive predictive value and negative predictive value for CIN2þ and
CIN3þ and speciﬁcity for oCIN2 and oCIN3.
HPV test Sensitivity (95%CI) Speciﬁcity (95%CI) PPV (95% CI)
Age
CIN2þ (N¼79)
Xpert
All 98.7 (93.1–99.8) 82.3 (81.0–83. 6) 11.7 (9.3–14.4)
20–29 100 (93.1–100) 63.4 (59.9–66.8) 15.5 (11.8–19.8)
30–60 96.3 (81.0–99.4) 89.3 (88.1–90.4) 7.8 (5.2–11.3)
COBAS
All 97.5 (91.1–99.6) 82.7 (81.4–84.0) 11.8 (9.4–14.5)
20–29 98.1 (89.7–99.68) 63.2 (59.7–66.6) 15.2 (11.5–19.5)
30–60 96.3 (81.0–99.4) 88.6 (87.3–89.8) 8.2 (5.4–11.8)
hc2
All 98.7 (93.1–99.8) 82.3 (80.9–83.6) 11.7 (9.3–14.4)
20–29 100 (93.1–100) 65.3 (61.8–68.6) 16.2 (12.3–20.7)
30–60 96.3 (81.0–99.4) 87.0 (85.7–88.3) 7.3 (4.8–10.5)
CIN3þ (N¼47)
Xpert
All 100 (92.4–100) 81.52 (80.2–82.8) 7.0 (5.2–9.3)
20–29 100 (89.3–100) 61.8 (58.4–65.2) 9.8 (6.9–13.5)
30–60 100 (76.7–100) 87.6 (86.3–88.9) 4.2 (2.3–7.0)
COBAS
All 97.9 (88.7–99.6) 81.9 (80.6–83.2) 7.0 (5.2–9.3)
20–29 97.0 (84.2–99.5) 61.7 (58.2–65.1) 9.5 (6.6–13.2)
30–60 100 (76.7–100) 88.2 (86.9–89.4) 4.4 (2.4–7.3)
hc2
All 100 (92.4–100) 81.2 (79.9–82.5) 6.9 (5.1–9.1)
20–29 100 (89.3–100) 63.7 (60.3–67.1) 10.3 (7.2–14.1)
30–60 100 (76.7–100) 86.6 (85.3–87.9) 3.9 (2.2–6.5)
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